Trial Profile
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Relacorilant (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Acronyms CORT125134-452
- Sponsors Corcept Therapeutics
- 02 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 02 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 23 Sep 2021 Planned End Date changed from 1 Jul 2021 to 1 Dec 2022.